ISSN: 0973-7510

E-ISSN: 2581-690X

Review Article | Open Access
Mukesh Kumar Sharma1,2 , Moh. Rizvan1, Nayeem Ahmad3, Puneet Jain1 and Mohan Kumar1
1Department of Biotechnology, Maharaj Vinayak Global University, Jaipur – 302 028, Rajasthan, India.
2Department of Botany, Vishwa Bharti PG College, Sikar – 332 001, Rajasthan, India.
3Western Diagnostic Lab, Meerut, Uttar Pradesh, India.
Article Number: 7720 | © The Author(s). 2022
J Pure Appl Microbiol. 2022;16(3):1575-1589.
Received: 17 March 2022 | Accepted: 30 June 2022 | Published online: 27 August 2022
Issue online: September 2022

Antimicrobial resistance is a serious public health concern across the world. Gram-negative resistance has propagated over the globe via various methods, the most challenging of which include extended-spectrum β-lactamases, carbapenemases, and AmpC enzymes. Gram-negative bacterial infections are difficult to treat in critically extremely sick persons. Resistance to different antibiotic treatments nearly always lowers the probability of proper empirical coverage, sometimes resulting in severe outcomes. Multidrug resistance can be combated with varying degrees of success using a combination of older drugs with high toxicity levels and novel therapeutics. The current therapies for multidrug-resistant Gram-negative bacteria are discussed in this review, which includes innovative medications, older pharmaceuticals, creative combinations of the two, and therapeutic targets.


MDR, ICU, Extended-spectrum β-lactamases, β-lactam/β-lactamase Inhibitors, AmpC Enzymes, Carbapenemases

Article Metrics

Article View: 420

Share This Article

© The Author(s) 2022. Open Access. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License which permits unrestricted use, sharing, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.